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A B S T R A C T
Objective: Pomegranate contains remarkable amounts of phenolic ingredients and it has been related to the
antioxidant capacity of this fruit. Several primary studies show that pomegranate intake can improve antioxidant
status. The objective of this systematic review and meta-analysis consisted in investigating the eﬀect of pome-
granate on oxidative stress (OS) parameters.
Methods: A comprehensive electronic database search in Scopus, Web of science, Embase, Cochrane library and
Medline was performed to identify eligible randomized controlled trials (RCTs). A meta-analysis of included
studies was performed on selected variables using a random-eﬀects model. Quality assessment was conducted by
means of Cochrane risk of bias assessment tool.
Results: Systematic search yielded 575 references. A total of 11 RCTs reporting data from 484 participants
included. Meta-analysis of data from 11 included RCTs did not support convincing evidence as to a signiﬁcant
increasing eﬀect of pomegranate intake in TAC (SMD: 0.43 ; 95 %CI: -0.19, 1.06), Gpx (SMD: 0.18, 95 % CI:
-0.25, 0.62, p = 0.4) and paraxonase (SMD: 0.36, 95 % CI: -0.50, 1.22, p= 0.41) as well as not signiﬁcant
decrease in Malondialdehyde (MDA) (SMD: -0.81, 95 % CI: -1.79, 0.09, P = 0.08).
Conclusion: Future well-designed clinical trials are needed before deﬁnite conclusive claims can be made about
the eﬀect of pomegranate on OS parameters.
1. Introduction
All cells under normal physiological conditions in the body are ex-
posed to endogenous and exogenous oxidants.1 Oxidative stress (OS)
deﬁned as an imbalance between the production of reactive oxygen/
nitrogen species (ROS/RNS) and the cell’s capacity to neutralize them
by the anti-oxidative protection systems.2 Electron transport chain
(ETC) in the inner membrane of mitochondria is the main source of
ROS, where the energy is produced. Electrons are given from NADPH
and FADH2 to oxygen by the help of four membrane complexes.3 As a
natural occurrence, some electrons are leaking from the inner mem-
brane to react with oxygen and form superoxide anions, which can then
generates other forms of ROS and also RNS.2 Increased ROS/RNS
generation or impaired ability of anti-oxidant production are the cause
of OS emerging, which showed the reduction of endogenous system
capacity to ﬁght against oxidative attack.4 ROS/RNS can damage and
modify diﬀerent types of macromolecules in the cell, like DNA, RNA,
proteins and lipids, these process can generate more potent reactive
molecules too.5 It was conﬁrmed that OS is associated with various
disorders and diseases.6–10 On the other hand, OS maybe can be pre-
vented by antioxidant potential manifestation at the proper site. So the
pathological consequences or even cell death of reactive species activity
will be impaired.11
Endogenous antioxidant defense system includes some enzymes
(like superoxide dismutase, glutathione peroxidase and catalase) and
non-enzymatic compounds such as proteins (ceruloplasmin, ferritin,
transferrin, and also albumin), glutathione and some scavengers like
coenzyme Q, uric acid and lipoic acid.12 In addition, exogenous
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antioxidants has a remarkable role respectively. Fruits and vegetables
contain antioxidants which can counterpart the activity of the en-
dogenous antioxidant defense.13 Antioxidant and anti-inﬂammatory
eﬀects of poly phenols have been conﬁrmed previously.14Studies have
demonstrated that the chemical structure of plant polyphenols is ap-
propriate for reactive species scavenging, and also in vitro studies the
eﬀectiveness of poly phenols antioxidant activity is more than ascorbate
and tocopherols.15 Instead of supplements, using naturally occurring
phytonutrients for limiting or reducing the OS is cost-eﬀective and also
a better way to make healthier behaviors.16
Pomegranate is a fruit which is a good source of polyphenols and
other compounds such as ﬂavonols, ﬂavonoids, quercetin, gallic acid,
ellagic acid, ellagitannins, nitrate.17,18 Pomegranate also contains an-
thocyanins like cyanidin, delphanidin and pelargonidin and other tan-
nins like punicalin, pedunculagin and punicalagin.19,20 Previous studies
showed that pomegranate juice (PJ) are potential in lowering the lipid
proﬁle parameters and homocysteine.21 In vitro studies show anti-
microbial eﬀect of PJ.22 Compared to other juices (such as other fruit
juices or black tea and green tea), PJ has more and better eﬀects on
increasing the body antioxidant capacity and decreasing oxidative da-
mages to biomolecules.23 In addition, pomegranate economically con-
sidered as a health-beneﬁcial food, and it has an abundant place in the
international commercial markets.24 Studies showed that prodelphini-
dines treatment has an inhibition eﬀects on cyclooxygenase-2 and li-
poxygenase activity, prostaglandin E2 production and type 2 collagen
synthesis activation in human chondrocytes.25,26In overall view, potent
mechanisms mediating the antioxidant properties of PJ is still unclear,
but its eﬀects has been attributed to increase polyphenol bioavailability
in comparison to other foods which are rich in polyphenols.27 Studies
regarding the beneﬁcial eﬀects of PJ on improving OS are controversial.
Several studies have shown beneﬁcial eﬀects of PJ on OS markers while
no signiﬁcant changes were seen in others. Therefore, we conducted a
systematic review and meta-analysis of the beneﬁcial eﬀects of PJ on
controlling OS factors.
2. Methods
This research was conducted according to the guidelines of the 2009
preferred reporting items for systematic reviews and meta-analysis
(PRISMA) statement.28 We perform meta-analyses of existing evidence
based on the ability of pomegranate to alter OS parameters compared to
placebo in either healthy individuals or patients.
2.1. Search strategy
Two separate electronic searches were conducted to identify RCT
relating intake of pomegranate to measures or changes of OS para-
meters. The search was performed in the following databases: Embase,
SCOPUS (http://www.scopus.com), Web of Science, Cochrane Library
and Medline (http://www.ncbi.nlm.nih.gov/pubmed) up to 15th
January 2019. Keywords included the following mesh terms (for
Medline) or subject headings (For Web of Science, Embase, Scopus and
Cochrane Library): Glutathione Reductase OR Reductase, Glutathione
OR Glutathione Peroxidase OR Peroxidase Glutathione OR Superoxide
Dismutase OR Dismutase Superoxide OR Oxidative Stress OR Stress
Oxidative OR Stress, Oxidative OR Total Antioxidant Capacity OR Total
Antioxidant Status OR antioxidant OR Oxidant OR reactive oxygen
species OR Catalase OR Oxygen Radical Absorbance OR reactive ni-
trogen species OR protein carbonyl OR lipid peroxide OR Total Radical
Trapping Antioxidant Parameter OR Malondialdehyde OR Nitric oxide
OR 8-hydroxydeoxyguanosine OR thiobarbituric acid reactive sub-
stances OR nitrotyrosine OR sulfhydryl group OR oxidized LDL lipo-
protein OR xanthine oxidase OR paraoxonase-1 AND Pomegranate OR
Pomegranate juice OR Pomegranate extract (PE) OR Punicaceae OR
Punica granatum. The sequence used is described in Appendix 1. No
language limitation was used in the literature search. The search was
restricted to studies in human.
2.2. Study selection
Two reviewers independently evaluated titles and abstracts of all
identiﬁed studies. Abstracts were read to determine and include articles
that fulﬁlled the selection criteria. Disagreements in opinion as to
whether articles should be included for full review were ﬁrstly dis-
cussed and resolved by consensus. If no consensus could be attained, a
third reviewer intervened to determine the inclusion or exclusion of the
study. Parallel or case-cross-over trial studies were included. Studies
assessing the impact of PJ on OS parameters, conducted in a range of
age between 18 and 80 years old. Studies should report enough in-
formation on beginning and at the end of study in both pomegranate
and control groups. Studies were excluded if they are non-clinical stu-
dies, uncontrolled trials or administering pomegranate preparations via
non-oral routes e.g. mouthrinse or topical application. Additionally,
literature reviews, case–control studies, cohort studies, case reports,
letter to editors, anthropological studies, in vitro studies or comments
were also excluded.
2.3. Data extraction and quality assessments
Data extraction and quality assessment were performed separately
by two reviewers (J.H. and M.S.). Information extracted from the ar-
ticles included: (1) ﬁrst author's name; (2) time of publication in year;
(3) Country where study is done; (4) number of subjects in the pome-
granate and control groups; (5) dose of supplementation with pome-
granate products; (6) duration of intervention; (7) serum concentrations
of TAC, GlutathionePeroxidase (Gpx), Malondialdehyde (MDA), thio-
barbituric acid reactive substances (TBARS), paraoxonase (8) and also
age and gender of participants. A systematic assessment of bias in the
included articles was carried out independently by two reviewers (J.H.
and M.M) using the Cochrane criteria.29 The criteria’s used for the
evaluation of each study were included: The assessment included se-
lection bias (method for random sequence generation and allocation
concealment), performance bias (blinding of participants and per-
sonnel), detection bias (blinding of outcome assessment), attrition bias
(incomplete outcome data), reporting bias (selective reporting) and
other sources of bias.
2.4. Data analysis
Studies that compared mid-term or long-term interventions of po-
megranate content were analyzed. Meta-analyses were performed using
Review Manager software (Version 5.2, The Nordic Cochrane Centre,
Copenhagen) if two or more articles examined pomegranate with the
same outcome measure. Signiﬁcant heterogeneity was detected
(P< 0.05, I2> 75 %); hence, a random-eﬀects model was conducted
for the meta-analysis. For continuous outcomes, standardized mean
diﬀerences (SMD) with 95 % conﬁdence intervals (CIs) were calculated.
Statistical analysis for heterogeneity was evaluated using the I2 statistic
to determine total variation across articles attributable to heterogeneity
and chi square test for heterogeneity.29,41 Meta-analysis results are
presented as forest plots.
3. Results
3.1. Description of the studies
Fig. 1 shows the study ﬂow diagram. Our systematic search of
electronic database yielded 575 references. Reference lists of relevant
articles were manually searched and elicited 6 additional studies. After
removing duplicates, title and abstract review resulted in 355 original
articles. A total of 11 RCTs reporting data from 484 participants were
ﬁnally fulﬁlled selection criteria and included in this systematic review
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Fig. 1. From: Moher D, Liberati A, Tetzlaﬀ J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The
PRISMA Statement. PLoS Med 6(7): e1000097. doi:https://doi.org/10.1371/journal.pmed1000097.
For more information, visit www.prisma-statement.org.
Table 1
Main characteristics of included studies.





30 ↓MDA, ↑ CAT, ↑ GPx P J 21.00 21.00 9 Tunisia Atheletes Elite weightlifters Healthy
adults
72
31 ↑ GPx, ↔MDA P E 48.40 49.10 55 Iran Rheumatoid Arthritis patients 8
32 ↓MDA P E 42 Iran Overweight + obese 4
33 ↓MDA, ↓AOPP P J 65.90 67.50 101 Israel Hemodialysis patients 48
34 ↓MDA, ↑ GPx, ↑ SOD, ↑
TAC
P J 19.07 19.78 28 Iran Healthy adults, males 2
35 ↑ GPx, ↑ MMP P J 56.74 53.84 38 Iran Knee osteoarthritis 6
36 ↑ GPx, ↔TAC P J 46.5 47.5 50 Iran D M type 2 8
37 ↓ox-LDL, ↑TAC, ↑PON P J 54.6 55.3 60 Iran D M type 2 6
38 ↑PON-1, ↔Ox-LDL P J 55.9 52.6 33 USA Hemodialysis Patients 24
39 ↑ GPx, ↑ SOD, ↑ TAC,
↑GSH
P J 56.5 49.5 33 Iran D M type 2, women, menopause 6
40 ↓TBARS P J 35 Egypt healthy adults 3
MDA: malondialdehyde, CAT: catalase, GPx: glutathione peroxidase, AOPP: advanced oxidation protein product, SOD: superoxide dismutase, TAC: total antioxidant
capacity, MMP: matrix metalloproteinase, ox-LDL: oxidized LDL, PON: paraoxonase, GSH: glutathione, TBARS: thiobarbituric acid reactive substances.
DM type -2 = Diabetes Mellitus type-2; PE = Pomegranate extract; PJ = Pomegranate juice.
* ↓ This symbol is a sign of decreasing variables in the intervention group, ↑ This symbol is a sign of increasing variables in the intervention group, ↔ This sign
indicates that there is no diﬀerence between the two groups. NR: not reported.
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and are illustrated in detail in Table 1. All identiﬁed studies were
published after 2012. One study was conducted in the United States,38
two were from Africa30,40 and eight were from Asia.31–37,39 The dura-
tion between the pomegranate interventions was wide and ranged from
2 to 72 weeks. All of the studies except one36 were written in English.
The mean age of the participants ranged from 21 to 65 years. The study
sample size was always rather small, with the ranging from nine30 to
one hundred and one.33 The potential eﬀect of PJ were used in nine
articles, while PE were used in another two studies. The participants
belonged to the elite weightlifters,30 rheumatoid arthritis patients,31
overweight and obese individuals,32 hemodialysis patients,33,38 patients
with kneeosteoarthritis,35 Type 2 diabetes patient36,37,39 and healthy
participants.34,40 MDA, TAC, Gpx and paraxonase were fullﬁled criteria
to be included in quantitative analyses and TBARS reported in quali-
tative assessment. MDA was assessed in ﬁve studies, TAC was assessed
in three studies, Gpx and paraxonase were assessed in two studies and
TBARS was assessed in one included study.
3.2. Quality assessment
Four of the selected articles did not report enough data about
random sequence generation30,34,35,40 and ﬁve of included studies did
not report a clear information about allocation conceal-
ment.30,34,36,39,40 Six of included studies not providing information or
with enough data about blinding.30,32,34,36,39,40 Nevertheless, other
possible sources of bias were report correctly by most of the included
studies. Details on the risk of bias assessment among included studies
are summarized in Appendix S2.
3.3. The eﬀect of pomegranate on serum levels of MDA
Fig. 2 shows a forest plot of the pooled eﬀect of pomegranate on
serum MDA concentrations. MDA levels in various samples were re-
ported in a total of ﬁve studies conducted in 244 participants. Four of
these RCTs shows a signiﬁcant reduction in MDA concentration after
pomegranate intake compare to placebo, while one of these shows no
signiﬁcant change of MDA. Meta-analysis of data from ﬁve studies re-
vealed no signiﬁcant change in serum MDA following treatment with
pomegranate (SMD: -0.81, 95 % CI: -1.79, 0.09, P = 0.08). This eﬀect
also has a large heterogeneity (Q = 39.24, P< 0.0001; I2 = 90 %).
3.4. The eﬀect of pomegranate on serum levels of TAC
The pooled SMD of three RCTs showed a non-signiﬁcant increase in
TAC in the pomegranate group compared with the placebo group (0.43
; 95 %CI: -0.19, 1.06) (Fig. 3). The heterogenicity of this eﬀect was I2=
49 %. In Mazani et al34 and Yarmohammadi et al39 pomegranate ef-
fectively increased the TAC levels, However, in the other study no
signiﬁcant result was reported.36
3.5. The eﬀect of pomegranate on serum levels of GPx
In six studies, the eﬀect of pomegranate consumption on Gpx levels
was evaluated, but due to diﬀerences in measurement units, only two
studies found the ability to enter the meta-analysis model. Meta-
analysis of data from two trials indicated a non-signiﬁcant elevation of
serum Gpx following pomegranate intake (SMD: 0.18, 95 % CI: -0.25,
0.62, p = 0.4) (Fig. 4), this eﬀect had no heterogenisity (I2:0 %; p =
0.91).
3.6. The eﬀect of pomegranate on serum levels of paraoxonase
Two studies have examined the eﬀect of pomegranate consumption
on serum paraoxonase levels, and Meta-analysis of these studies results
are presented in Fig. 5. Meta-analysis represented a non-signiﬁcant
change of serum paraoxonase following pomegranate intake (SMD:
0.36, 95 % CI: -0.50, 1.22, p = 0.41) (Fig. 5), this eﬀect has dramati-
cally high heterogenisity (I2=72 %; p = 0.91).
3.7. The eﬀect of pomegranate on TBARS
Only one study which measuring urinary TBARS levels have fulﬁlled
the criterias to entering this systematic review. Gouda et al. 40showed
that pomegranate consumption reduced the amount of Urinary TBARS.
4. Discussion
Pomegranate has been represented as a polyphenol-rich fruit with
expanded health valuable good eﬀects due to its high antioxidative
potential.42 In the present systematic review and meta-analysis of RCTs,
pomegranate was not associated with a statistically signiﬁcant altera-
tion in OS parameters (MDA, TAC, Gpx, and paraoxonase). Although
small number of articles were included in this systematic review, all the
included studies found a signiﬁcant improvement on various serum OS
parameters. All the included articles were RCTs which increased the
power of their study. Nonetheless, due to diﬀerences such as duration of
intervention, number of subjects, pomegranate dosage, diﬀerent vari-
ables and values and also variable inconsistency made it hard to reach a
certain conclusion in this ﬁeld of study.
To the best of our knowledge, this is the ﬁrst pooled estimate of the
eﬀects of PJ on OS parameters. Our study showed that the consumption
of pomegranate causes an insigniﬁcant decrease in MDA levels.
Although this relationship has a very high heterogeneity, this indicates
a very high diﬀerence between the studies. Therefore, if more homo-
geneous studies were available in this ﬁeld, maybe a more resolute
conclusion could be made in this regard. The lack of knowledge about
the possible mechanism of pomegranate could be described by the di-
versity of fruit ingredients.43,44 The antioxidant power of compounds
found in pomegranate is proven in extensive in vitro and animal stu-
dies.45 Tannins and polyphenols present in pomegranate considered as
factors aﬀecting the antioxidant properties of pomegranate. Pome-
granate may have anti lipid peroxidation eﬀects due to reduction of
platelet aggregation, LDL oxidation and macrophage oxidative
status.46,47
In our study, the results of meta-analysis showed that pomegranate
did not have a signiﬁcant eﬀect on glutathione peroxidase levels. GSH-
Pxis the one of the main abundant antioxidant markers in serum and
have an important role in ROS scavenging based on in vitro studies.48
Although previous studies have shown that PJ increases the antioxidant
defense.31,35 However, the antioxidant eﬀects of the wide range of
Fig. 2. Forest plot of pomegranate on serum MDA levels.
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polyphenols present in pomegranate can reduce ROS levels in the body,
therefore the body also needs to produce less glutathione to antioxidant
defense.45 Our study also showed that pomegranate causes a non-sig-
niﬁcant increase in TAC levels, which according to previous studies
about the antioxidant properties of pomegranates, if there were more
studies in this ﬁeld that entered into the meta-analytical model, maybe
the results would be signiﬁcant. The results of this meta-analysis
showed that pomegranate causes an insigniﬁcant increase in para-
oxonase levels. Increased paraoxonase after pomegranate intake con-
ﬁrm antioxidative properties of pomegranate polyphenols including
ellagic acid, anthocyanin,tannins, and punicalagin which are powerful
ROS scavengers.49,50 Eﬀect of Pomegranate intake on urinary TBARS
was also investigated in early studies40 and positive eﬀects of pome-
granate have been observed in reducing this oxidant index. This study
has some limitations. The limited number of studies for each of the OS
variables made it impossible to conclude certainly about the eﬀect of
pomegranate on the OS parameters. In addition dramatically high
heterogeneity of the primary studies, included in this systematic review
also did not reveal a clear picture of the pomegranate antioxidant ef-
fects.
5. Conclusion
Eventually, according to the results of the present systematic re-
view, pomegranate has positive eﬀects on OS parameters. However,
based on the Meta-Analysis, because of not enough clinical trials and
variable inconsistency no resolute conclusion could be made on the
eﬀect of pomegranate on OS parameters. Future clinical trials with
large sample size and well design to remove the limitations in the ex-
isting literature are necessary before deﬁnite claims can be made about
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